Business as usual has not been the mantra for companies developing Covid-19 vaccines and drugs.
Instead, biopharma companies and their partners pursued various transformational approaches to get vaccines and treatments to market at unprecedented speeds. These included adaptive trials, master protocols, real-world evidence, and other approaches powered by advanced statistical techniques, data science, and analytics using curated datasets.
